OCUL · Ocular Therapeutix, Inc · Documents

Feb 28

Earnings call

Q4 2021 earnings call

Feb 28

Current report 8-K

Financial results

Feb 28

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Revenue $43.52M ▲ 150.1% Net loss $6.55M Diluted EPS -$0.98

Feb 7

Current report 8-K Events of Feb 3

Director or officer change, or executive pay

Nov 8

Earnings call

Q3 2021 earnings call

Nov 8

Current report 8-K

Financial results

Nov 8

Quarterly report 10-Q FY2021 Q3, ended Sep 30

Quarterly report for FY2021 Q3

Revenue $12.15M ▲ 106.8% Net income $2.66M Diluted EPS -$0.23

Sep 22

Current report 8-K Events of Sep 20

Director or officer change, or executive pay

Aug 9

Current report 8-K

Financial results

Aug 9

Current report 8-K

Entered into a material agreement, Other events

Aug 9

Quarterly report 10-Q FY2021 Q2, ended Jun 30

Quarterly report for FY2021 Q2

Revenue $11.72M ▲ 646.8% Net loss $8.48M Diluted EPS -$0.25

Jul 22

Earnings call

Q2 2021 earnings call

Jul 22

Current report 8-K

Financial results

Jun 22

Current report 8-K Events of Jun 18

Director or officer change, or executive pay, Charter or bylaw amendment, or fiscal year change, Shareholder vote results

Jun 4

Current report 8-K

Entered into a material agreement

May 5

Current report 8-K

Financial results

May 5

Quarterly report 10-Q FY2021 Q1, ended Mar 31

Quarterly report for FY2021 Q1

Revenue $7.34M ▲ 181.4% Net income $3.12M Diluted EPS -$0.24

Apr 29

Proxy statement DEF 14A Meeting Jun 18, 2021

Proxy statement

Apr 29

Earnings call

Q1 2021 earnings call

Apr 29

Current report 8-K

Financial results

Apr 29

Proxy statement DEFA14A

Proxy statement

Apr 27

Current report 8-K

Director or officer change, or executive pay

Apr 13

Proxy statement PRE 14A

Proxy statement

Mar 11

Current report 8-K

Financial results

Mar 11

Annual report 10-K FY2020, ended Dec 31

Annual report for FY2020

Revenue $17.4M ▲ 311.7% Net loss $155.64M

Feb 12

Current report 8-K

Regulation FD disclosure

Jan 20

Current report 8-K

Regulation FD disclosure

Jan 11

Earnings call

Q4 2020 earnings call

Jan 11

Current report 8-K

Financial results, Regulation FD disclosure

Dec 18

Current report 8-K Events of Dec 15

Entered into a material agreement, Other events

Dec 14

Current report 8-K

Other events

Dec 14

Registration statement S-3ASR

Registration statement

Nov 5

Earnings call

Q3 2020 earnings call

Nov 5

Current report 8-K

Financial results

Nov 5

Quarterly report 10-Q FY2020 Q3, ended Sep 30

Quarterly report for FY2020 Q3

Revenue $5.88M ▲ 608.8% Net loss $11.94M Diluted EPS -$0.21

Oct 30

Current report 8-K Events of Oct 29

Entered into a material agreement

Oct 16

Current report 8-K Events of Oct 13

Entered into a material agreement, Other events

Oct 13

Current report 8-K

Other events

Oct 7

Current report 8-K

Financial results

Aug 7

Current report 8-K

Financial results

Aug 7

Quarterly report 10-Q FY2020 Q2, ended Jun 30

Quarterly report for FY2020 Q2

Revenue $1.57M ▲ 141.4% Net loss $36.57M

Jul 17

Earnings call

Q2 2020 earnings call

Jul 17

Current report 8-K

Financial results

Jul 16

Current report 8-K

Financial results, Regulation FD disclosure

Jul 6

Current report 8-K

Other events

Jul 1

Current report 8-K Events of Jun 25

Shareholder vote results

Jun 15

Proxy statement DEFA14A

Proxy statement

May 22

Current report 8-K Events of May 19

Entered into a material agreement, Other events

May 14

Current report 8-K Events of May 8

Entered into a material agreement, Other events

May 8

Earnings call

Q1 2020 earnings call